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This is a descriptive cross-sectional study, which aimed to analyze the health related quality 
of life (HRQoL) and its relationship with gender, age, duration and indication for the use of 
oral anticoagulants. A total of 178 patients were interviewed and the HRQoL was assessed 
through eight domains of the SF-36. The descriptive statistics used were, the Student’s 
t, ANOVA and Tukey’s tests for the comparison of the means between the groups. The 
indication for use was predominantly the metallic prosthetic heart valve (50%) with warfarin 
the most widely prescribed anticoagulant (83.3%). The means of the domains of the SF-
36 ranged from 82 (Social aspects) to 54.8 (Physical aspects). Women, elderly, patients 
diagnosed with atrial fibrillation and with less than one year of medication use, presented 
a worse HRQoL evaluation. The results obtained can guide nursing actions, in that they 
indicate possible associations between the HRQoL and the sociodemographic and clinical 
variables of the patients.
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Qualidade de vida relacionada à saúde de pacientes em uso de 
anticoagulação oral
Trata-se de estudo descritivo, tipo corte transversal, que teve como objetivo analisar a 
qualidade de vida relacionada à saúde (QVRS) e sua relação com sexo, idade, tempo e 
indicação para o uso de anticoagulantes orais. Foram entrevistados 178 pacientes e a 
QVRS foi avaliada pelos oito domínios do SF-36. Usaram-se estatística descritiva, testes 
t de Student, ANOVA e Tukey para comparação das médias entre os grupos. A indicação 
para o uso foi predominantemente a prótese cardíaca metálica (50%) e a varfarina 
o anticoagulante mais prescrito (83,3%). As médias dos domínios do SF-36 variaram 
de 82 (aspectos sociais) a 54,8 (aspectos físicos). Mulheres, idosos e pacientes, com 
diagnóstico de fibrilação atrial e menos de um ano de uso do medicamento, apresentaram 
pior avaliação da QVRS. Os resultados obtidos podem nortear ações de enfermagem, na 
medida em que indica possíveis associações entre a QVRS e variáveis sociodemográficas 
e clínicas dos pacientes.
Descritores: Qualidade de Vida; Anticoagulantes; Assistência Ambulatorial.
Calidad de vida relacionada a la salud de pacientes que usan 
anticoagulación oral
Se trata de un estudio descriptivo, de tipo corte transversal, que tuvo como objetivo 
analizar la calidad de vida relacionada a la salud (CVRS) y su relación con sexo, 
edad, tiempo e indicación de uso de anticoagulantes orales. Fueron entrevistados 
178 pacientes y la CVRS fue evaluada por los ocho dominios del SF-36. Fue utilizada 
estadística descriptiva, las pruebas: t Student, ANOVA y Tukey, para comparación de 
los promedios entre los grupos. La indicación para el uso fue predominantemente la 
prótesis cardíaca metálica (50%) y la warfarina el anticoagulante más prescrito (83,3%). 
Los promedios de los dominios del SF-36 variaron de 82 (Aspectos sociales) a 54,8 
(Aspectos físicos). Mujeres, ancianos, y pacientes con diagnóstico de fibrilación atrial y 
con menos de un año de uso del medicamento, presentaron peor evaluación de la CVRS. 
Los resultados obtenidos pueden orientar acciones de enfermería, en la medida en que 
indican posibles asociaciones entre la CVRS y las variables sociodemográficas y clínicas 
de los pacientes.
Descriptores: Calidad de Vida; Anticoagulantes; Atención Ambulatoria.
Introduction
Some cardiovascular diseases precipitate an 
unwanted blood coagulation action requiring the use 
of oral anticoagulants (OACs). The clinical applications 
of OACs have been evidenced through studies of 
various conditions, such as atrial fibrillation, venous 
thromboembolism, patients with prosthetic heart valves, 
congestive heart failure, myocardial infarction and other 
special situations(1). The therapeutic action of the OAC 
can be influenced by numerous conditions that alter its 
absorption and metabolism. The intake of foods rich in 
fats and vitamin K, drugs containing acetylsalicylic acid 
and alcohol can be cited as examples. The changes in 
the desired levels of blood anticoagulation can cause 
hemorrhagic or thromboembolic events, harming the 
patient(1). For the evaluation of the anticoagulation levels, 
laboratory control is accomplished through frequent 
blood sampling in order to obtain the International 
Normalized Ratio (INR)(2). Currently, for most patients, 
the maintenance of moderate intensity anticoagulation 
is recommended, i.e. with INR values  ranging from 2 to 
3. This interval may vary according to the indications for 
the oral anticoagulant(3-4).
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The use of OACs requires some care in order to 
control the desirable levels of blood coagulation and to 
prevent hemorrhagic and thromboembolic complications. 
Such care can lead to changes in the lifestyle of users 
since this involves changes in the dietary habits, the use 
of alcohol and the performance of physical activity(5-6), as 
well as the overload caused by new tasks related to the 
use of medication, such as the habit of daily ingestion 
of the medication and the need for frequent visits to 
health services for monitoring of the anticoagulation 
range, and the fear of complications such as bleeding 
and thrombus formation(7). All these changes caused by 
the use of the drug may impair the quality of life of the 
patient. The term health related quality of life (HRQoL) 
has been used when the concern of researchers is to 
investigate the influence of the disease and treatment 
on the quality of life of the individual(8). This narrower 
concept has been used to avoid ambiguity between the 
definition of quality of life in the common sense and that 
used in clinical and medical trials, which is the focus of 
this study.
The evaluation of patients regarding the effects of 
the use of oral anticoagulants also deserves investigation. 
A study published in the early 1990s(5) has already 
pointed out the negative effects of oral anticoagulants 
in the evaluation of the health status of the patients, 
when related to the presence of collateral effects of the 
medication. The fear of the occurrence of bleeding also 
caused increased anxiety in those individuals who had 
experienced this complication of the treatment. In oral 
anticoagulation therapy, as in other therapies for chronic 
conditions, the acceptance of the individuals, with 
reference to changing habits and behaviors, is necessary 
to be able to prevent later complications. Therefore, the 
success of each therapy depends on how each individual 
perceives its benefits(5). Positive perceptions are related 
to a better control of the oral anticoagulation therapy 
and better HRQoL(6), with the reduction of the number 
of oral anticoagulation therapy complications associated 
with improved HRQoL(1).
In order to study the HRQoL of the users of oral 
anticoagulants, authors have used different types of 
instruments. Some authors used a measurement of 
HRQoL obtained through the generic instrument the 
Medical Outcomes Survey 36-item Short Form (SF-36)
(6,9-12) and found that the more impaired HRQoL domains 
were Physical aspects and Vitality(6,10), Pain(11), Physical 
functioning and General health status(6). In Brazil, in a 
study that followed patients for the first six months of oral 
anticoagulation therapy, the author found that the mean 
values of the SF-36 domains ranged from 32.4 (Physical 
aspects) to 82.7 (Social aspects) at the beginning of the 
treatment. Six months after the beginning of the OAC 
therapy, the means of the domains were higher and 
ranged from 72.1 (Vitality) to 90.7 (Social aspects)(12). 
The measurement of HRQoL obtained by the SF-36 was 
also used in a study that evaluated the psychometric 
properties of an adherence instrument, aimed at 
patients using OACs(13). In a literature review regarding 
specific instruments available to evaluate the HRQoL of 
patients using OACs, the authors identified only seven 
instruments(14). In Brazil, one of these instruments, 
the Duke Anticoagulation Satisfaction Scale(11), was 
recently validated(15), and its use permitted the finding 
of improvements in the HRQoL six months after starting 
treatment, especially in the Psychological impact 
domain(12).
The HRQoL of patients using OAC and the quality 
of the oral anticoagulation therapy have been associated 
with sociodemographic (age and gender) and clinical 
variables (indication for and the duration of the oral 
anticoagulation therapy)(6,12,16). In the clinical practice of 
nurses, they are increasingly faced with patients using 
OAC under their care. A better understanding of the 
profile of these individuals and the impact of this therapy 
on the HRQoL will contribute to better planning of this 
care. Considering the scarcity of published Brazilian 
studies that investigate the HRQoL of patients receiving 
oral anticoagulation(12), this study proposed to answer 
the following questions:
- What is the health related quality of life of patients 
using oral anticoagulants, in outpatient monitoring?
- Is there a difference between the health related quality 
of life of patients using oral anticoagulants according to 
the variables gender and age?
- Is there a difference between the health related quality 
of life of patients using oral anticoagulants according to 
the variables indication for the use of oral anticoagulants 
and duration of the therapy?
Given the above, this study aimed to analyze the 
HRQoL and its relationship with gender, age, duration 
and indication for use of oral anticoagulants.
Method
Design, population and ethical aspects: This is a 
descriptive cross-sectional study performed in an oral 
anticoagulation outpatient clinic of a teaching hospital in 
the State of São Paulo. The sample was non-probabilistic 
and consisted of 178 patients who attended the service 
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for evaluation of blood coagulation, verified by INR, in 
the period from March to August 2008 and that met the 
following inclusion criteria: to be 18 years of age or more 
and to be treated with OACs for at least two months. 
The exclusion criteria were: to have cognitive or verbal 
difficulty to respond to the instruments of the study, or 
to have a reported diagnosis of psychiatric disorders in 
the medical record.
The project was approved by the Research Ethics 
Committee of the institution where the study was 
conducted under process No. 6738/2007. All participants 
signed the Terms of Free Prior Informed Consent, in 
duplicate, a copy of which was kept by the researchers 
and the other by the participant, in accordance with 
regulations of the National Health Council It was explained 
to each subject that their privacy and anonymity would 
be guaranteed.
The sociodemographic data collected were: age, 
gender, marital status, schooling, occupation and monthly 
family income. In addition, data were included, such as: 
the type of OAC, the indication for its use, duration of the 
treatment, weekly dose of the OAC, the last INR value, 
associated diseases recorded in the medical records, and 
other medication in use. The evaluation of the HRQoL 
was obtained through the instrument Medical Outcomes 
Survey 36-Item Short-Form (SF-36)(17), in its validated 
Portuguese version(18). This instrument consists of 36 
items, of which 35 items are grouped into eight domains: 
Functional capacity (10 items), Physical aspects (four), 
Pain (two), General health status (five), Vitality (four), 
Social aspects (two), Emotional aspects (three), Mental 
health (five) and one more question of the comparative 
evaluation between the current evaluation of the health 
condition of the individual and the condition a year ago. 
Each domain presents values on a scale of zero to 100, 
with higher values indicating better perceived health 
status or HRQoL(18). In the present study, the Cronbach’s 
alpha values obtained ranged from 0.97 (Emotional 
aspects) to 0.69 (Social aspects), indicating good 
internal consistency of the items in the group studied.
The data were analyzed using the program 
Statistical Package for the Social Sciences (SPSS) 
version 15.0. Descriptive analysis was performed for 
the sociodemographic and clinical data and for the 
scores of the SF-36. The Student’s t test was used to 
verify the differences between the means of the HRQoL 
measurements, according to gender. To compare the 
means of HRQoL according to age (less than 40 years, 
between 40 and 59 years, and 60 years or older), 
indications for the oral anticoagulation therapy (metallic 
prosthetic heart valve, atrial fibrillation, and other 
indications), and duration of medication use (up to 1 
year, 1 to 3 years, 3 to 5 years, 5 to 10 years, and over 
10 years) Analysis of Variance (ANOVA) and Tukey’s test 
were performed. The level of significance adopted was 
0.05.
Results
Regarding the sociodemographic and clinical 
characteristics of the 178 subjects studied, the 
majority were female (116; 65.2%), married (116; 
65.2%), retired (65; 36.9%), with mean age of 55.6 
years (ranging from 24.8 to 86.1) and with complete 
elementary education (126; 70.8%). Warfarin sodium 
was the most prescribed anticoagulant (83.1%), with 
an mean dose of 33.6 mg/week, with the indication for 
oral anticoagulation predominantly for individuals using 
metallic prosthetic heart valves (50.6%), followed by 
atrial fibrillation sufferers (33.1%). The mean duration 
of use of the OAC was seven years, with 2.4 as the mean 
value of the last INR. With regard to the presence of 
other comorbidities, it was found that the most prevalent 
were Arterial Hypertension (91; 51.1%), Arrhythmias 
(85; 47.8%) and Coronary Artery Disease (77; 43.3%), 
with the prescription of antihypertensive drugs (116; 
65.2%) and diuretics (99; 55.6%) associated with the 
use of OACs.
Regarding the evaluation of the HRQoL a better 
evaluation was obtained for Social aspects ( x =82, 
SD=26.6) and worse for Physical aspects ( x =54.8, 
SD=47.8). The other six domains of the SF-36 varied 
between 66.5 (Mental health) and 62.9 (Emotional 
aspects). To evaluate the presence of differences in the 
HRQoL according to age, the subjects were separated 
into three age groups: less than 40 years (n=24), 
between 40 and 59 years (n=83) and 60 years or older 
(n=71). Statistically significant differences were found 
between the groups in the domains Physical functioning 
(p=0.012) and Pain (p=0.024) (Table 1). The comparison 
of multiple means using Tukey’s test indicated that for 
the Physical functioning domain, the differences were 
statistically significant between the patients in the age 
group less than 40 years ( x  = 77.7) and those of 40 
to 59 years ( x = 61.5, p=0.028) and the patients of 
less than 40 years and those 60 years or older( x = 
60.2, p=0.018). Regarding the Pain domain, there was 
a statistically significant difference only when comparing 
the group 60 years or older ( x = 66.3) with the group 
between 40 and 59 years ( x = 54.6) (p=0.043).
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Table 1 - Comparison of the means of the domains of the SF-36, according to the age of the subjects
Domains of the SF-36
Less than 40 years Between 40 and 59 years 60 years or older
p*
Mean (sd) Mean (sd) Mean (sd)
Physical functioning 77.7 (20.3) 61.5 (30.3) 60.2 (24.4) 0.012
Pain 66.0 (31.0) 54.6 (29.5) 66.3 (29.7) 0.024
Vitality 65.2 (27.0) 62.4 (24.9) 70.2 (23.3) 0.11
Mental health 63.3 (28.2) 64.1 (25.4) 70.2 (23.6) 0.30
General Health Status 63.7 (27.2) 70.4 (24.0) 69.2 (24.7) 0.56
Physical aspects 58.3 (48.1) 57.2 (47.4) 50.7 (48.5) 0.61
Social Aspects 76.0 (32.9) 81.5 (26.7) 84.7 (24.0) 0.67
Emotional aspects 58.3 (50.4) 61.4 (48.4) 66.2 (47.3) 0.71
* ANOVA test
When comparing HRQoL according to the gender 
of the subjects, statistically significant differences were 
observed in the domains Mental health (p=0.008) and 
Pain (p=0.019), the best evaluation being for males, 
with mean values  of 74 and 68 respectively (Table 2).
Table 2 - Comparison of the means of the domains of the SF-36, according to the gender of the subjects
Domains of the SF-36
Women Men
p*
Mean (sd) Mean (sd)
Mental health 62.4 (27.0) 74.0 (19.2) 0.008
Pain 57.0 (30.3) 68.0 (28.8) 0.019
Emotional aspects 58.5 (48.9) 70.9 (45.7) 0.096
Physical functioning 61.7 (27.7) 67.0 (26.4) 0.16
Vitality 63.7 ( 26.5) 70.0 (20.4) 0.24
Social Aspects 80.5 (28.4) 84.9 (22.9) 0.42
Physical aspects 53.3 (48.3) 57.7 (47.2) 0.58
General Health Status 69.5 (25.1) 68.0 (24.1) 0.60
* Student’s t test.
The HRQoL of the participants was evaluated 
considering the indication for the oral anticoagulation 
therapy, grouped into three categories: metallic 
prosthetic heart valve (n=90), atrial fibrillation (n=59) 
and other indications (n =29). Statistically significant 
differences were found between the individuals, with 
regard to the domains Physical aspects (p=0.040) and 
Physical functioning (p=0.030) (Table 3). Tukey’s test 
indicated that for the Physical functioning domain, the 
differences were statistically significant between the 
patients with metallic prosthetic heart valves ( x = 
68.3) and those with the indication due to the presence 
of atrial fibrillation ( x = 56.6, p=0.028). Regarding 
the Physical aspects domain, there were statistically 
significant differences between patients with metallic 
prosthetic heart valves ( x =64.2) and those with atrial 
fibrillation ( x = 46.1, p=0.04) and those with other 
indications ( x =43.5, p=0.048).
Table 3 - Comparison of the means of the domains of the SF-36, according to clinical indication for oral anticoagulant 
use
Domains of the SF-36
Metallic prosthetic heart valve Atrial fibrillation Other indications
p*
Mean (sd)
n=90
Mean (sd)
n= 59
Mean (sd)
n= 29
Physical functioning 68.3 (25.9) 56.6 (27.8) 60.8 (28.2) 0.030
Physical aspects 64.2 (45.6) 46.1 (48.2) 43.1 (49.5) 0.040
Pain 60.8 (32.0) 57.3 (29.0) 67.7 (26.3) 0.31
Vitality 67.3 (24.8) 63.6 (24.4) 66.0 (25.5) 0.56
Social Aspects 83.9 (24.9) 80.7 (27.7) 78.9 (29.9) 0.58
Mental health 68.2 (23.8) 66.2 (26.1) 61.6 (27.5) 0.59
General health status 70.9 (22.7) 67.4 (26.7) 66.2 (26.7) 0.62
Emotional aspects 62.6 (47.9) 62.0 (48.9) 65.5 (48.4) 0.94
* ANOVA test
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Regarding the differences in HRQoL according to the 
duration of medication use, the subjects were grouped 
into five categories: up to one year (n=23), one to three 
years (n=37), three to five years (n=25), five to ten 
years (n=50) and over ten years (n=43). There were 
statistically significant differences between the groups in 
the domains Physical functioning (p=0.000) and General 
health status (p=0.023)(Table 4). The use of Tukey’s 
test showed that for the Physical functioning domain, 
the differences were statistically significant between the 
patients with over 10 years use of OAC ( x =77.8) and 
those with up to one year of use ( x =51.9, p=0.002) and 
with patients with three to five years of use ( x =64.0, 
p=0.000). Regarding the General health status domain, 
there were statistically significant differences between 
the patients with over ten years of use ( x =77.8) and 
those with up to one year ( x =57.1, p=0.023).
Table 4 - Comparison of the means of the domains of the SF-36, according to the duration of the use of oral 
anticoagulants of the subjects
Domains of the 
SF-36
Up to 1 year 1 to 3 years 3 to 5 years 5 to 10 years Over 10 years
p*
Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd)
Physical functioning 51.9 (29.5) 64.4 (28.2) 64.0 (26.2) 54.5 (27.7) 77.8 (18.5) 0.000
General health status 57.1 (28.6) 67.70 (24.9) 74.9 (22.3) 66.3 (24.6) 76.2 (21.5) 0.023
Physical aspects 43.4 (48.4) 51.4 (49.9) 43.0 (48.7) 52.0 (48.1) 73.8 (40.8) 0.066
Vitality 59.8 (31.9) 63.5 (22.5) 64.6 (25.9) 64.0 (24.2) 74.2 (20.8) 0.16
Social aspects 69.5 (35.7) 78.7 (29.4) 88.5 (17.3) 81.2 (27.0) 88.7 (19.6) 0.19
Mental health 56.5 (31.0) 63.9 (23.8) 67.0 (23.3) 67.6 (24.5) 72.4 (23.8) 0.21
Emotional aspects 52.1 (51.0) 55.5 (50.4) 69.3 (46.0) 60.0 (48.5) 74.4 (44.1) 0.27
Pain 58.2 (28.6) 58.7 (27.1) 58.2 (33.0) 60.2 (31.7) 66.2 (29.7) 0.75
* ANOVA test
Discussion
The present study verified a greater participation 
of women using oral anticoagulants, a result similar 
to that found by other investigators(6,12,16), however, 
in other studies, researchers have mainly evaluated 
males(5,11,15,19-20). The group was composed of subjects 
of various ages, with 40% over 60 years of age. Similar 
results were found in other studies(16,19-22). It should be 
noted that the site in which the study was conducted 
is a tertiary level public hospital, characterized by 
its care, teaching and research activities. In this 
hospital, the majority of patients are attended in 
the Brazilian National Health System (SUS), being a 
reference for various specialties, including outpatient 
oral anticoagulation therapy, serving this region of São 
Paulo State. Thus, this data would justify the majority 
of the individuals having low schooling levels (mean 4.6 
years of formal study). Among the studies reviewed, 
few refer to this data in the characterization of their 
participants, however, in those that have included 
such information, it was found that the participants 
presented higher education levels than the participants 
of this study(6,11,16). The two main indications for oral 
anticoagulant use among the study subjects were 
the use of metallic prosthetic heart valves (50.6%) 
and the presence of atrial fibrillation (33.1%), with 
these indications also prevalent in other populations 
investigated(6,12,20). Other studies have found the 
prevalence of various indications, including: as a result 
of acute myocardial infarction(11) and the presence of a 
pacemaker(10). These indications were also present in 
this study, however, due to the low frequency observed, 
were grouped under “other indications”. Warfarin was 
the most prescribed oral anticoagulant among the 
participants, corroborating the literature data(10,22).
In the present study the investigation was 
undertaken of the health related quality of life of patients 
using oral anticoagulants, which is justified by the 
clinical complexity of the study group, in which various 
aspects of the health and treatment may influence their 
quality of life. Among the eight domains of the SF-36, 
the highest evaluation was for Social aspects and the 
worse, for Physical aspects, with the other domains 
having similar means between 60.8 (Pain) and 69.0 
(General health status). In a study performed with 
North American patients, the authors obtained similar 
results, with regard to the domain with better evaluation 
(Social aspects) and with the worst evaluation (Physical 
aspects). However, in other domains, such as Physical 
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functioning, Vitality and General health status, the 
patients presented mean scores below 50, whereas in 
the present study, the values  were above 60(12). A study 
performed with Argentinean patients(6), although the 
more compromised domain was Pain, domains such as 
Physical functioning ( x = 50.0), Vitality ( x = 54.4) and 
General health status ( x =53.7) also had mean values 
below those found among the subjects of this study.
When comparing the measurements of HRQoL 
in relation to the age of the participants, statistically 
significant differences were only found for the domains 
Physical functioning and Pain. For the Physical 
functioning domain, the best evaluation was obtained 
from the subjects under 40 years of age and the worst 
for those over 60 years. This result confirms that young 
individuals present better physical functioning, i.e. less 
physical limitation to carry out activities (vigorous 
or activities of daily living), when compared to the 
elderly(6). The domain Pain had the best evaluation 
among the elderly and the worst among individuals 
aged between 40 and 59 years. Thus, among the 
elderly, a lower frequency was found of reports of 
pain and less interference of the oral anticoagulants 
in their lives, given that generally they had previously 
presented other chronic conditions associated with the 
situation that led to the use of anticoagulants, possibly 
being just another medication among the various other 
medications that they need to use chronically.
When comparing the HRQoL measurements 
according to gender, the men had higher scores than 
the women, in the majority of the domains of the SF-
36, except for General health status. However, these 
differences were only statistically significant in the 
domains Mental health and Pain. Similar results were 
found in other studies(6,20,23). It is believed that this could 
be due to the fact that men give less importance to 
healthcare, often delegating this responsibility to their 
wives.
Statistically significant differences were found for 
the measurements of the domains Physical aspects 
(p=0.04) and Physical functioning (p=0.03), presented 
in the three groups of patients classified according to 
clinical indication of the OAC. In this first domain, the 
patients with an indication due to the use of metallic 
prosthetic heart valve had better evaluations than the 
others. In the second domain, Physical functioning, the 
subjects with metallic prostheses also presented higher 
scores, followed by those with other clinical indications. 
These results were also observed in a previous study(6), 
in which the authors verified a better evaluation of 
the HRQoL in individuals with metallic prosthetic heart 
valves, compared to individuals diagnosed with atrial 
fibrillation.
HRQoL also differed when the subjects were 
evaluated according to duration of the use of OAC. A 
better HRQoL was verified among those in long-term 
treatment (over 10 years of use) and worse for those 
with short durations (less than one year). Other patients 
with less than one year of therapy also presented low SF-
36 scores(6). These results suggest that the relationship 
of HRQoL with the duration of OAC use may be related to 
the period of adaptation and change of habits resulting 
from the therapy, in the initial months of the treatment. 
Thus, individuals with longer use could have already 
adapted, with regard to changing eating habits and 
behavior, as well as to the dosage and possible collateral 
effects of the medication.
Conclusion
The evaluation of health related quality of life in 
individuals using oral anticoagulants presented a better 
evaluation for the Social aspects domain and worse for 
the Physical aspects domain. When compared, according 
to the sociodemographic and clinical variables, the health 
related quality of life had a worse evaluation among 
women, the elderly, those with less than one year of 
therapy, and those with a diagnosis of atrial fibrillation 
or other indication for oral anticoagulant use.
Considering the scarcity of studies involving the 
theme of HRQoL and oral anticoagulation, it is believed 
that the presented results can guide nursing actions 
directed toward the group of individuals who present a 
worse HRQoL evaluation, in that the variables gender, 
age, indication and duration of use of the OACs present 
associations with some of the HRQoL domains. Such 
data may help in the prevention of events that may 
negatively affect the quality of life of these users, as 
well as providing a base for the health professionals 
in the planning of individual care, so that the therapy 
can be as painless as possible for each patient, as they 
naturally demand certain precautions concerning the 
control of blood coagulation. Thus, the development 
of future studies is proposed, with longitudinal designs 
and the use of instruments specific to measuring the 
HRQoL in individuals using OAC in order to obtain 
strong evidence on which to base the conduct of health 
professionals in relation to oral anticoagulant users.
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